Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term." 2. Burlington Stores (BURL) downgraded to Neutral from Outperform at Credit Suisse with analyst Christian Buss saying that although the fundamentals of the company remain healthy, he sees limited upside to valuation as the multiples stay elevated despite more moderate industry growth prospects. 3. Big 5 Sporting (BGFV) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Baker saying he expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." 4. Ultimate Software (ULTI) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi calling the second quarter results "mixed" and prefers to move to the sidelines until growth returns to the mid-20s target and leverage returns to the model. 5. ResMed (RMD) was downgraded to Neutral from Buy at BofA/Merrill and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

KeyBanc raised the firm's price target on ResMed to $238 from $227 and keeps an Overweight rating on the shares. KeyBanc was incrementally encouraged by broad outperformance in Q3, especially given difficult year over year comps in Devices as well as near-term concerns around the potential impacts of GLP-1s, the analyst tells investors in a research note.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Reports Q3 revenue $1.2B, consensus $1.17B. "ResMed's strong third-quarter fiscal year 2024 results reflect robust patient and customer demand for our products and software solutions, leading to double-digit mask and accessories revenue growth along with ongoing operational efficiencies to drive margin improvement and increased profitability, resulting in double-digit growth in both operating profit and earnings per share," said Mick Farrell, ResMed's Chairman & CEO. "Over 2 billion people worldwide can benefit from a ResMed solution to help them sleep better, breathe better, and receive best-in-class healthcare right where they live. We remain laser-focused on bringing market-leading innovation to customers, including our latest AirCurve11 range of non-invasive ventilators and our recently launched AirFit F40 mask system, combined with our entire portfolio of products, software, and solutions, allowing us to continue to deliver value for all our stakeholders."